April 02, 2019
WELLESLEY, Mass., April 2, 2019–Strong growth in epigenetics and diagnostic arrays will help propel the global cancer profiling and pathways market, according to a report by BCC Research.
The industry expects to see a compound annual growth rate (CAGR) of 14.9% through 2023, when it could be worth $90.6 billion, according to the report, “Cancer Profiling and Pathways: Technologies and Global Markets.”
“North America is the largest center for the cancer/tumor profiling market, followed by Europe and Asia,” notes report author Usha Nagavarapu. “Both North America and Europe are expected to grow at a steady pace during the forecast years. However, the Asia-Pacific market and a few countries from the ROW region are also expected to witness a boost in demand and are poised to register maximum growth over the next five years, owing to affected populations, high incidence of cancers and the increased purchasing power of patients.”
United States Leads Market by Size, With Asia Seeing Strong Growth
The United States currently leads the market by size and holds a significant share of the world market, the report adds, with Europe and the Asia-Pacific region following. The Asian market, however, is poised to see the highest growth through the forecast period, with a CAGR of 16%.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at email@example.com.
Cancer Profiling and Pathways: Technologies and Global Markets( BIO073C )
Publish Date: Mar 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.